ERBB2 and triple-negative breast carcinoma: Other bispecific mAbs in clinical use or trials are: Cinrebafusp alfa (PRS-343), a bispecific fusion protein targeting both HER2/4-1BB on tumor cells and T cells, currently in phase I of clinical trial (NCT03330561) for HER2-positive tumor patients [14,15,16]; and KN046, an IgG1 bsAb targeting both PD-L1 and CTLA-4, currently in a phase I clinical trial (NCT03529526) on metastatic triple negative breast cancer [17,18,19].